Focal therapy for localized prostate cancer – Current status

Atluri, Shrikanth; Mouzannar, Ali; Venkatramani, Vivek; Parekh, Dipen J.; Nahar, Bruno

doi:10.4103/iju.iju_166_21

Cited by 2 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, a myriad of focal treatment modalities is available for the ablation of prostate cancer. These encompass cryotherapy, high-intensity focused ultrasound (HIFU), irreversible electroporation, photodynamic therapy, and focal brachytherapy [13].…”

Section: Discussionmentioning

confidence: 99%

“…Photodynamic therapy (PDT) shares some similarities with FLA, as it also employs transperineally inserted optical fibers directed at the prostate target. However, it is noteworthy that Azzouzi et al reported a notable rate of 38% for erectile dysfunction and urinary complications associated with PDT [13].…”

Section: Discussionmentioning

confidence: 99%

“…A study on the irreversible electroporation investigated 63 patients and reported a 16% of in-field recurrence with a mild decline in the sexual quality-of-life score [13]. Within focal brachytherapy, seeds are transperineally inserted into the prostate.…”

Section: Discussionmentioning

confidence: 99%

“…King et al conducted an evaluation of 354 patients who underwent brachytherapy focused on the peripheral zone, revealing long-term oncologic results that are concerning. Specifically, they reported a 10-year biochemical progression-free survival rate of only 28% for patients with intermediate-risk prostate cancer [13].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

Manenti,

Perretta,

Nezzo

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: This interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low–intermediate-risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: Forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low-to-intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical and functional assessments through the international index of erectile function (IIEF-5) and the International Prostatism Symptom Score (IPSS), PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: Forty patients were initially included, with fifteen lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible, and effective in the index lesion treatment of low–intermediate-risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

Manenti,

Perretta,

Nezzo

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

A Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablation

Kadria-Vili,

Schwartz,

Polascik

et al. 2024

Nanomaterials

View full text Add to dashboard Cite

AuroLase® Therapy—a nanoparticle-enabled focal therapy—has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with AuroLase, providing insight on expectations from the diagnosis of PCa to one year post-treatment. AuroLase Therapy is a two-day treatment consisting of a systemic infusion of gold nanoshells (~150-nm hydrodynamic diameter) on Day 1, and sub-ablative laser treatment on Day 2. Multiparametric MRI (mpMRI) was used for tumor visualization, treatment planning, and therapy response assessment. The PCa was targeted with a MR/Ultrasound-fusion (MR/US) transperineal approach. Successful treatment was confirmed at 6 and 12 months post-treatment by the absence of disease in MR/US targeted biopsies. On the mpMRI, confined void space was evident, an indication of necrotic tissues encompassing the treated lesion, which was completely resolved at 12 months, forming a band-like scar with no evidence of recurrent tumor. The patient’s urinary and sexual functions were unchanged. During the one-year follow-up, changes on the DCE sequence and in the Ktrans and ADC values assist in qualitatively and quantitatively evaluating tissue changes. The results highlight the potential of gold-nanoparticle-enabled sub-ablative laser treatment to target and control localized PCa, maintain quality of life, and preserve baseline functionality.

show abstract

Focal therapy for localized prostate cancer – Current status

Cited by 2 publications

References 44 publications

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

A Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablation

Contact Info

Product

Resources

About